Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The class action lawsuit has been filed against RxSight, Inc. for allegedly misleading statements regarding the company's growth and performance during the Class Period [4] - Investors who purchased RxSight securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [2] Group 2: Allegations Against RxSight - The lawsuit claims that RxSight misrepresented the effectiveness of its field organization and the adoption rates of newer customer cohorts, which were actually underperforming [4] - It is alleged that the utilization across the installed base was declining, contradicting the company's claims of rising utilization [4] - As a result of these misleading statements, investors purchased shares at artificially inflated prices, leading to financial damages when the truth was revealed [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [3]

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the company's growth and performance during the specified Class Period [1][4]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company specializing in cataract treatment, with its main product being the RxSight Light Adjustable Lens system, which includes an intraocular light adjustable lens and a light delivery device [3]. Allegations of the Lawsuit - The lawsuit claims that RxSight and its executives misrepresented the company's growth, stating that utilization was rising and that newer customer cohorts were adopting the technology at a comparable or faster rate than previous cohorts. In reality, the company faced challenges with its field organization, leading to slower adoption and declining utilization [4]. - The lawsuit highlights that incremental placements of light delivery devices did not result in the expected volume of lens procedures, undermining the company's growth model [4]. Impact of Disclosures - On April 2, 2025, RxSight reported a sequential decline in quarterly lens sales and reduced its full-year revenue guidance by approximately $24 million, resulting in a 38% drop in the stock price [5]. - Further disclosures on July 8, 2025, revealed a 45% sequential decline in light delivery device sales and a second consecutive quarter of declining lens sales, leading to another 38% decrease in stock price [6]. Legal Representation - The plaintiffs in the lawsuit are represented by Robbins Geller Rudman & Dowd LLP, a law firm with significant experience in prosecuting investor class actions related to financial fraud [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action lawsuit has been filed against RxSight, and investors who purchased securities between May 7, 2024, and July 8, 2025, may be entitled to compensation without any out-of-pocket fees [1][2] - Investors wishing to serve as lead plaintiff must file a motion with the Court by September 22, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that RxSight misrepresented the performance of its field organization and the adoption rates of newer customer cohorts, leading to inflated stock prices [4] - It is claimed that the actual utilization across the installed base was declining, contradicting the company's statements about growth and support [4]